Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 15, 2021 (the "Effective Date"), the board of directors (the
"Board") of Amesite Inc. (the "Company") authorized and approved the termination
of Matthew Kern as Chief Financial Officer of the Company, effective as of the
Effective Date.
In addition, on December 15, 2021, in connection with the termination of Mr.
Kern, the Board authorized and approved the appointment of Mark Corrao, age 64,
as Chief Financial Officer of the Company. The Company entered into a CFO
Agreement with Mr. Corrao, a copy of which is filed as Exhibit 10.1 hereto.
There are no family relationships between Mr. Corrao and any other director or
officer of the Company. Mr. Corrao has not engaged in any transactions described
in Item 404(a) of Regulation S-K. Set forth below is the biographical
information of Mr. Corrao, as required by Item 401 of Regulation S-K.
Mr. Corrao has extensive experience in public accounting, specializing in
certified auditing, SEC accounting, corporate taxation and financial planning.
Since 2012, Mr. Corrao has served as the Chief Financial Officer of Neuropathix,
Inc. (OTCQB:NPTX), a drug development company. From 2012 to 2020, Mr. Corrao was
a Managing Director of The CFO Squad LLC, an accounting and consulting services
firm, and he currently serves as an advisor to the company. From 2018 to 2021,
Mr. Corrao served as the Chief Financial Officer for Brain Scientific, Inc., a
medical device company. From 2017 to 2021, Mr. Corrao served as the Chief
Financial Officer for Generex Biotechnology Corporation (OTCQB:GNBT), a drug
development company, and its subsidiaries. From 2015 to 2017, Mr. Corrao served
as the Chairman of the Audit Committee for Success Holdings Group International.
In 2003, Mr. Corrao founded Strikeforce Technologies, Inc. (OTCQB:SFOR), a
publicly traded software development and services company, serving as the Chief
Financial Officer until 2010 and a director until 2013. Mr. Corrao's background
also includes previous experience on Wall Street with Merrill Lynch, Spear Leeds
& Kellogg, and Greenfield Arbitrage Partners.
Item 9.01 Financial Statements and Exhibits
Exhibits
Exhibit No. Description
10.1 Corrao CFO Agreement
104 Cover Page Interactive Data File (embedded within Inline XBRL document)
-1-
© Edgar Online, source Glimpses